<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592995</url>
  </required_header>
  <id_info>
    <org_study_id>2006P001640</org_study_id>
    <secondary_id>P01NS058793</secondary_id>
    <nct_id>NCT00592995</nct_id>
  </id_info>
  <brief_title>Creatine Safety and Tolerability in Premanifest HD: PRECREST</brief_title>
  <acronym>PRECREST</acronym>
  <official_title>Creatine Safety and Tolerability in Premanifest HD: PRECREST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRECREST is a two phase protocol for Huntington's disease in which 60 premanifest and at-risk
      subjects will first be randomized into a double blind placebo controlled dose titration study
      bringing them to 30 grams daily or their highest tolerated dose. This phase will establish
      the highest tolerable doses in premanifest HD and permit the detection of toxicity and
      intolerability with attribution to active compound versus placebo, and enable a dose response
      assessment of biomarkers. In the second phase, all subjects will enter a year long open-label
      treatment on 30 grams daily (or their highest dose) of creatine to assess long term exposure
      to high dose creatine and its long term impact on various biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extensive evidence exists that neurodegeneration begins many years before HD can be diagnosed
      clinically. Therefore, it is most desirable to begin a neuroprotective therapy before or
      during this premanifest period with the aim of delaying onset, as well as slowing functional
      decline. Cellular energy depletion is present early in HD and can be ameliorated by creatine,
      which helps regenerate cellular ATP. Preclinical evidence for creatine's potential
      neuroprotective effects in animal models of HD has been well-documented. Before the clinical
      efficacy of creatine can be tested in premanifest HD, its long-term safety and tolerability
      must be assessed in these individuals and its ability to favorably modify biomarkers of HD
      should also be confirmed. A two phase protocol is proposed in which 60 premanifest and
      at-risk subjects will randomized into a double blind placebo controlled dose titration study
      bringing them to 30 grams daily or their highest tolerated dose. The placebo-controlled phase
      will permit the detection of toxicity and intolerability due to the active compound
      (creatine), and enable a dose response assessment of biomarkers. In the second phase, all
      subjects will enter a year long open-label treatment on 30 grams daily of creatine. This
      phase will maximize the subjects on active compound to promote recruitment and retention, to
      expand assessment of safety data on all subjects, and increase the power to detect and
      measure potential biological markers and any response to the active compound. The clinical
      impact of creatine will be assessed using the United Huntington's Disease Rating Scale.
      Safety and tolerability will be assessed by analyzing clinical and laboratory adverse events.
      Serum levels of creatine will be used to assess compliance and whether there is a
      relationship between bioavailability and response. 8OH2'dG and related markers will be
      assessed to determine whether creatine treatment can chronically suppress markers of energy
      depletion and oxidative injury and whether suppression correlates with slowing the
      progression of HD. Morphometric MRI will be used to determine whether creatine can slow brain
      atrophy in premanifest HD. This study will provide the pilot data needed to plan a future
      study to determine whether creatine can delay the onset or slow the progress of HD in
      premanifest individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of Study (tolerability)</measure>
    <time_frame>18 Months</time_frame>
    <description>Tolerability (proportion of subjects completing study at given dose level)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>18 Months</time_frame>
    <description>Frequency of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic and Pharmacodynamic biomarkers</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UHDRS</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Volumetric &amp; Neurochemical Changes</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics &amp; Gene Expression Biomarkers</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creatine monohydrate</intervention_name>
    <description>10 to 30 grams daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 to 30 grams daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Expansion positive or 50% at risk for HD and not diagnosed clinically

        Exclusion Criteria:

        - Unstable medical conditions

        Additional inclusion and exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Hersch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.</citation>
    <PMID>20460152</PMID>
  </reference>
  <reference>
    <citation>Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006 Jan 24;66(2):250-2.</citation>
    <PMID>16434666</PMID>
  </reference>
  <reference>
    <citation>Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207. Epub 2005 Aug 1. Review.</citation>
    <PMID>16055197</PMID>
  </reference>
  <reference>
    <citation>Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003 Jun;85(6):1359-67.</citation>
    <PMID>12787055</PMID>
  </reference>
  <reference>
    <citation>Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis. 2001 Jun;8(3):479-91.</citation>
    <PMID>11447996</PMID>
  </reference>
  <reference>
    <citation>Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000 Jun 15;20(12):4389-97.</citation>
    <PMID>10844007</PMID>
  </reference>
  <reference>
    <citation>Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci. 2007 Nov 21;27(47):12908-15.</citation>
    <PMID>18032664</PMID>
  </reference>
  <reference>
    <citation>Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010 Dec 14;75(24):2150-60. doi: 10.1212/WNL.0b013e3182020123. Epub 2010 Nov 10.</citation>
    <PMID>21068430</PMID>
  </reference>
  <reference>
    <citation>Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH, Salat DH, Hersch SM. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical &quot;disconnection&quot;. Neuroimage. 2010 Feb 15;49(4):2995-3004. doi: 10.1016/j.neuroimage.2009.10.015. Epub 2009 Oct 19.</citation>
    <PMID>19850138</PMID>
  </reference>
  <reference>
    <citation>Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci. 2008 Dec;1147:196-205. doi: 10.1196/annals.1427.034. Review.</citation>
    <PMID>19076442</PMID>
  </reference>
  <reference>
    <citation>Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.</citation>
    <PMID>18394565</PMID>
  </reference>
  <reference>
    <citation>Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008 Apr;131(Pt 4):1057-68. doi: 10.1093/brain/awn025. Epub 2008 Mar 12.</citation>
    <PMID>18337273</PMID>
  </reference>
  <reference>
    <citation>Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006 Sep;21(9):1317-25.</citation>
    <PMID>16755582</PMID>
  </reference>
  <reference>
    <citation>Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005 Sep 13;65(5):745-7.</citation>
    <PMID>16157910</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <disposition_first_submitted>January 10, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 10, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 10, 2014</disposition_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven M. Hersch</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

